Brad E. Hoffman

发表

Plant-based oral tolerance to hemophilia therapy employs a complex immune regulatory response including LAP+CD4+ T cells.

Xiaomei Wang, K. Leong, H. Daniell, 2015, Blood.

THROMBOSIS AND HEMOSTASIS Plant-based oral tolerance to hemophilia therapy employs a complex immune regulatory response including LAP 1 CD 4 1 T cells

Xiaomei Wang, K. Leong, H. Daniell, 2015 .

Liver induced transgene tolerance with AAV vectors.

D. Markusic, B. Hoffman, G. Keeler, 2017, Cellular immunology.

The Balance between CD8+ T Cell-Mediated Clearance of AAV-Encoded Antigen in the Liver and Tolerance Is Dependent on the Vector Dose.

R. Herzog, C. Terhorst, Y. D. de Jong, 2017, Molecular therapy : the journal of the American Society of Gene Therapy.

Ex vivo expanded autologous polyclonal regulatory T cells suppress inhibitor formation in hemophilia

R. Herzog, D. Markusic, T. Brusko, 2014, Molecular therapy. Methods & clinical development.

Covert warfare against the immune system: decoy capsids, stealth genomes, and suppressors.

R. Herzog, B. Hoffman, Brad E. Hoffman, 2013, Molecular therapy : the journal of the American Society of Gene Therapy.

AP-1 (Fos/Jun) transcription factors in hematopoietic differentiation and apoptosis.

B. Hoffman, D. Liebermann, B. Hoffman, 1998, International journal of oncology.

Type I IFN Sensing by cDCs and CD4+ T Cell Help Are Both Requisite for Cross-Priming of AAV Capsid-Specific CD8+ T Cells.

M. Wallet, L. Morel, R. Herzog, 2019, Molecular therapy : the journal of the American Society of Gene Therapy.

Regulatory T cells and TLR9 activation shape antibody formation to a secreted transgene product in AAV muscle gene transfer.

L. Morel, R. Herzog, C. Terhorst, 2017, Cellular immunology.

Plasmacytoid and conventional dendritic cells cooperate in crosspriming AAV capsid-specific CD8+ T cells.

M. Wallet, G. Rogers, R. Herzog, 2017, Blood.

Apoptosis of infiltrating T cells in the central nervous system of mice infected with Theiler's murine encephalomyelitis virus.

J. Gaughan, C. Katsetos, C. Platsoucas, 2003, Virology.

Nonredundant roles of IL-10 and TGF-β in suppression of immune responses to hepatic AAV-factor IX gene transfer.

B. Sack, R. Herzog, C. Terhorst, 2011, Molecular therapy : the journal of the American Society of Gene Therapy.

Gene Therapy-Induced Antigen-Specific Tregs Inhibit Neuro-inflammation and Reverse Disease in a Mouse Model of Multiple Sclerosis

D. Markusic, Brett Palaschak, B. Hoffman, 2017, Molecular therapy : the journal of the American Society of Gene Therapy.

AAV3-miRNA vectors for growth suppression of human hepatocellular carcinoma cells in vitro and human liver tumors in a murine xenograft model in vivo

A. Srivastava, K. Qing, C. Ling, 2020, Gene Therapy.

AAV3-miRNA vectors for growth suppression of human hepatocellular carcinoma cells in vitro and human liver tumors in a murine xenograft model in vivo

A. Srivastava, K. Qing, C. Ling, 2020, Gene Therapy.

Immunopathology of secondary‐progressive multiple sclerosis

E. Cho, M. Barnett, B. Morgan, 2001, Annals of neurology.

Reprogramming Immune Response With Capsid-Optimized AAV6 Vectors for Immunotherapy of Cancer

G. Aslanidi, C. Ling, M. Pandya, 2015, Journal of immunotherapy.

Prevention and Reversal of Antibody Responses Against Factor IX in Gene Therapy for Hemophilia B

B. Byrne, R. Herzog, Shangzhen Zhou, 2011, Front. Microbio..

Impact of the underlying mutation and the route of vector administration on immune responses to factor IX in gene therapy for hemophilia B.

H. Ertl, R. Herzog, K. High, 2009, Molecular therapy : the journal of the American Society of Gene Therapy.

Improved induction of immune tolerance to factor IX by hepatic AAV-8 gene transfer.

R. Herzog, C. Terhorst, O. Cao, 2009, Human gene therapy.

Hepatic gene transfer as a means of tolerance induction to transgene products.

R. Herzog, B. Hoffman, P. A. LoDuca, 2009, Current gene therapy.

Gene Therapy Research at the Frontiers of Viral Immunology

H. Ertl, R. Herzog, K. High, 2012, Front. Microbio..

Muscle as a target for supplementary factor IX gene transfer.

R. Herzog, F. Mingozzi, E. Dobrzynski, 2007, Human gene therapy.

Superior In vivo Transduction of Human Hepatocytes Using Engineered AAV3 Capsid.

C. Rice, Arun Srivastava, H. Ertl, 2016, Molecular therapy : the journal of the American Society of Gene Therapy.

Effective gene therapy for haemophilic mice with pathogenic factor IX antibodies

Xiaomei Wang, R. Herzog, K. High, 2013, EMBO molecular medicine.

Improved Adeno-associated Viral Gene Transfer to Murine Glioma.

R. Herzog, K. Warrington, I. Zolotukhin, 2013, Journal of genetic syndromes & gene therapy.

Type I Interferon Sensing by Conventional Dendritic Cells and CD4+ T Help are both Requisite for Cross-priming of AAV Capsid-specific CD8+ T Cells

M. Wallet, L. Morel, I. Zolotukhin, 2019 .

High-efficiency transduction and correction of murine hemophilia B using AAV2 vectors devoid of multiple surface-exposed tyrosines.

S. Zolotukhin, G. Jayandharan, L. Zhong, 2010, Molecular therapy : the journal of the American Society of Gene Therapy.

Alpha‐1 Antitrypsin‐Deficient Macrophages Have Increased Matriptase‐Mediated Proteolytic Activity

Farshid N. Rouhani, M. Brantly, G. Aslanidi, 2017, American journal of respiratory cell and molecular biology.

Potential for cellular stress response to hepatic factor VIII expression from AAV vector

R. Herzog, I. Zolotukhin, D. Markusic, 2016, Molecular therapy. Methods & clinical development.

Presence of Oligoclonal T Cells in Cerebrospinal Fluid of a Child with Multiphasic Disseminated Encephalomyelitis following Hepatitis A Virus Infection

C. Katsetos, A. Legido, H. Hardison, 2001, Clinical Diagnostic Laboratory Immunology.

Low cost delivery of proteins bioencapsulated in plant cells to human non-immune or immune modulatory cells.

H. Daniell, R. Herzog, Kwang-Chul Kwon, 2016, Biomaterials.

Oral delivery of bioencapsulated coagulation factor IX prevents inhibitor formation and fatal anaphylaxis in hemophilia B mice

H. Daniell, R. Herzog, D. Verma, 2010, Proceedings of the National Academy of Sciences.

Tolerance Induction to Cytoplasmic β-Galactosidase by Hepatic AAV Gene Transfer — Implications for Antigen Presentation and Immunotoxicity

B. Byrne, R. Herzog, D. Markusic, 2009, PloS one.

Induction of antigen-specific tolerance by hepatic AAV immunotherapy regardless of T cell epitope usage or mouse strain background

C. D. Gaddie, B. Hoffman, G. Keeler, 2022, Molecular therapy. Methods & clinical development.

Prophylactic immune tolerance induced by changing the ratio of antigen‐specific effector to regulatory T cells

R. Herzog, Shangzhen Zhou, O. Cao, 2009, Journal of thrombosis and haemostasis : JTH.

Upregulation of CD8+ regulatory T cells following liver-directed AAV gene therapy.

C. D. Gaddie, Kevin G Senior, Brad E. Hoffman, 2024, Cellular Immunology.

Dissection of the genetic programs of p53-mediated G1 growth arrest and apoptosis: blocking p53-induced apoptosis unmasks G1 arrest.

A. Giordano, C. Guillouf, B. Hoffman, 1995, Blood.

Tolerance Induction to Cytoplasmic \(\beta\)-galactosidase by Hepatic Aav Gene Transfer — Implications for Antigen Presentation and Immunotoxicity Tolerance Induction to Cytoplasmic B-galactosidase by Hepatic Aav Gene Transfer — Implications for Antigen Presentation and Immunotoxicity

R. Herzog, D. Markusic, C. Terhorst, 2022 .